Definium Therapeutics officer proposes $124K share sale
A separate line reports 3,013 common shares sold on June 25, 2026, alongside the proposed transaction.
Rhea-AI Filing Summary
Definium Therapeutics, Inc. (DFTX) officer Brandi Roberts reported a proposed sale of 3,377 common shares on September 25, 2026, with an aggregate market value of $124,037.21. The notice lists 134,367,000 shares outstanding and names Morgan Stanley Smith Barney LLC as broker. It also reports that Roberts sold 3,013 common shares on June 25, 2026, with an aggregate market value of $126,937.69.
Positive
- None.
Negative
- None.
Key Figures
Shares proposed for sale: 3,377 shares
Aggregate market value: $124,037.21
Shares outstanding: 134,367,000 shares
+2 more
5 metrics
Shares proposed for sale
3,377 shares
Proposed sale dated September 25, 2026
Aggregate market value
$124,037.21
Proposed sale of common shares
Shares outstanding
134,367,000 shares
Reported in the securities information
Shares sold during the past three months
3,013 shares
Sale reported for June 25, 2026
Aggregate market value
$126,937.69
Sale reported for June 25, 2026
Key Terms
Rule 144, Restricted Stock Vesting Under a Registered Plan
2 terms
Rule 144 regulatory
"definition of "person" in paragraph (a) of Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Vesting Under a Registered Plan financial
"Restricted Stock Vesting Under a Registered Plan"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.